플러스 테라퓨틱스PSTV 주가

Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today

Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology

Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision

♻️ 재탕[4] 내부자 거래 — 4

[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?